Clinical Trial Update: Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NS2330, a monoamine reuptake inhibitor, in Parkinson's disease has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• NS2330

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED